CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation

PRINCETON, N.J., Dec. 28, 2023 -- CytoSorbents Corporation , a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its...

Related Keywords

United States ,Canada ,Canadian ,America ,Irina Kulinets ,Efthymiosn Deliargyris ,Kathleen Bloch ,Us Air ,Astrazeneca ,Cytosorbents Corporation ,Facebook ,Human Services ,Us Army ,Breakthrough Devices Program ,Bus Company Contact ,Health Canada ,European Union ,National Heart ,Material Command ,Twitter ,Blood Institute ,National Institutes Of Health ,American College Of Cardiology ,Us Department Of Health ,Sorbents Corporation ,Safety Monitoring Board ,Timely Antithrombotic Removal ,American College ,Chief Medical Officer ,Senior Vice President ,Global Regulatory ,Latin America ,Middle East ,Breakthrough Device Designation ,Device Designation ,Devices Program ,Breakthrough Designation ,Use Authorization ,Device Designations ,Timely Antithrombotic Removal Ticagrelor ,National Institutes ,Operations Command ,Air Force Material Command ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Markets ,